← Human Trials & Peer-Reviewed Studies
Transient memory impairment after acute dose of 3.4-Methylene-dioxymethamphetamine.
Plain-language guide to PMID 16272186 (2005): double-blind randomized controlled trial of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 16272186
- Journal
- Journal of psychopharmacology (Oxford, England)
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Kuypers KP et al. (2 authors)
- DOI
- 10.1177/0269881105056670
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Methylene blue (non-peptide stack partner), published as a randomized controlled trial.
Yet it is difficult to determine whether these deficits are caused by MDMA or some other confounding factor, such as polydrug use.
Why It Was Studied
A range of studies has indicated that users of 3.4-Methylene-dioxymethamphetamine (MDMA, 'Ecstasy') display cognitive deficits, particularly memory impairment, as compared to non-drug using controls.
The present study was designed to establish the direct relation between MDMA and memory impairment under placebo-controlled conditions.
Who Took Part
PubMed indexes the participants as adults, both men and women.
How the Study Was Run
The design is described as randomized, double-blind, placebo-controlled and crossover.
Random assignment meant chance, not the researchers, decided who got Methylene blue (non-peptide stack partner) and who got the comparison, which limits bias.
Neither the participants nor the staff measuring them knew who was on Methylene blue (non-peptide stack partner), so expectations could not easily colour the readings.
The comparison arm used a placebo, so changes seen with Methylene blue (non-peptide stack partner) could be set against what happens without it.
Each person switched between Methylene blue (non-peptide stack partner) and the comparison at some point, usually with a gap in between.
What Was Measured
The subject headings attached to it are Affect, Amphetamine-Related Disorders, Discrimination Learning, Memory, Memory, Short-Term, Methylphenidate and N-Methyl-3,4-methylenedioxyamphetamine.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Methylene blue (non-peptide stack partner).
The publication is from 2005 (Journal of psychopharmacology (Oxford, England)), a journal based in United States.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.